Patents Examined by Prema Mertz
  • Variable region sequences of IL-31 monoclonal antibodies
    Patent number: 8101183
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: January 24, 2012
    Assignee: ZymoGentics, Inc.
    Inventors: Anthony W. Siadak, Shirley Rene
  • Peptide derived from vascular endothelial growth factor receptor-1 binding integrin ?5?1 having proangiogenic activity
    Patent number: 8093218
    Abstract: Description of a sequence peptide isolated in the domain II type-immunoglobulin (Type-Ig) of the Vascular Endothelial Growth Factor receptor 1 (VEGF-1) binding integrin ?5?1, usable for the preparation of pharmacological agents having proangiogenic activity.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: January 10, 2012
    Assignees: Provincia Italiana della Congregazione dei Figli dell'Immacolata Concezione-Istituto Dermopatico dell'Immacolata, Consiglio Nazionale delle Richerche, Universita' degli Studi di Roma “La Sapienza”
    Inventors: Stefania D'Atri, Cristina Maria Failla, Pedro Miguel Lacal, Angela Orecchia, Giovanna Zambruno, Anna Tramontano, Simonetta Soro, Veronica Morea
  • Nucleic acids encoding anti-IL-12 antibody
    Patent number: 8084233
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: December 27, 2011
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Recombinant human albumin-interleukin-11 fusion protein with long-lasting biological effects
    Patent number: 8084021
    Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: December 27, 2011
    Inventors: Zailin Yu, Yan Fu
  • Anti-IL-12 antibodies
    Patent number: 8080247
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: December 20, 2011
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Method of treating rheumatoid arthritis with an IL-6R antibody
    Patent number: 8080248
    Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: December 20, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Method of treatment using an anti-IL-B50 antibody
    Patent number: 8075886
    Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: December 13, 2011
    Assignee: Schering Corp
    Inventors: Pedro A. Reche-Gallardo, Vassili Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein
  • Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same
    Patent number: 8066980
    Abstract: Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and/or osteoarthritis.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: November 29, 2011
    Assignee: Industry Foundation of Chonnam National University
    Inventors: Taek Rim Yoon, Hyung Keun Kim, Ji Hyun Kim
  • Methods of treating conditions using anti-IL-6 antibodies
    Patent number: 8067003
    Abstract: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: November 29, 2011
    Assignees: Centocor, Inc., Applied Molecular Evolution, Inc.
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Methods of treating cutaneous ulcers and grafts using agonist antibodies to IL-23 receptor
    Patent number: 8062634
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: November 22, 2011
    Assignee: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • Treatment methods for fibrosis related disorders
    Patent number: 8057802
    Abstract: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: November 15, 2011
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Antibodies to stromal cell-derived factor-1 polypeptides
    Patent number: 8058403
    Abstract: Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: November 15, 2011
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Keting Chu, Lewis T. Williams, Justin G. P. Wong, Kevin Hestir, Amy L. Tsui Collins, Ernestine Lee
  • Molecular phenotyping of severe asthma
    Patent number: 8053199
    Abstract: The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.
    Type: Grant
    Filed: July 22, 2008
    Date of Patent: November 8, 2011
    Inventors: Allan R. Brasier, William J. Calhoun, Gary D. Boetticher
  • Human antibodies to human IL-6 receptor
    Patent number: 8043617
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: October 25, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Anti-IL-6/IL-6R antibodies and methods of use thereof
    Patent number: 8034344
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: October 11, 2011
    Assignee: NovImmune S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
    Patent number: 8030003
    Abstract: Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: October 4, 2011
    Assignee: Children's Hospital Medical Center
    Inventor: Marc Elliot Rothenberg
  • Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same
    Patent number: 8025872
    Abstract: Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and/or osteoarthritis.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: September 27, 2011
    Assignee: Industry Foundation of Chonnam National University
    Inventors: Taek Rim Yoon, Hyung Keun Kim, Ji Hyun Kim
  • Peptides and compositions for inhibiting fungal growth
    Patent number: 8026207
    Abstract: It is intended to provide a novel peptide which can exert higher antifungal effect also on a patient whose organ function is impaired with no side effect problems. The peptide comprises the following amino acid sequence: (1) SEQ ID NO:1: Lys -Arg-Leu-Phe-Arg-Arg-Trp-Gln-Trp-Arg-Tyr, (2) SEQ ID NO:2: Arg-Arg-Trp-Gln -Trp-Arg-Met-Lys-Lys-Tyr, (3) SEQ ID NO:3: Lys-Arg-Trp-Gln-TTp-Arg-Leu-Tyr, or (4) SEQ ID NO:4: Lys-Arg-Leu-Phe-Lys-Tyr, an antifungal agent comprising the peptide, a composition having a fungicidal and/or growth inhibitory action against fungus containing an effective amount of the peptide as an active ingredient, a medical apparatus/device which contains the peptide, whereby a fungicidal action is conferred, and a fungicidal and/or growth inhibiting method against fungus comprising administering the peptide and the like.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: September 27, 2011
    Assignees: Japan Science and Technology Agency, Hiroshima University, Two Cells Co., Ltd.
    Inventors: Hiroki Nikawa, Masahiro Nishimura, Koichiro Tsuiji, Ryoko Kawabata, Nobue Hiromoto
  • Methods of using IL-31 monoclonal antibodies to reduce inflammation
    Patent number: 8017122
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: September 13, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Antibodies to human zcytor17 ligand
    Patent number: 8013124
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: September 6, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Angela K. Hammond, Julia E. Novak